Loading...
•
Jun 30, 2023
Pulse Biosciences Q2 2023 Earnings Report
Announced financial results for the second quarter ended June 30, 2023.
Key Takeaways
Pulse Biosciences reported a GAAP net loss of $9.9 million for the three months ended June 30, 2023, compared to a $14.0 million loss for the same period in the prior year. Cash and cash equivalents totaled $58.7 million as of June 30, 2023.
Achieved encouraging preclinical results with nsPFA cardiac clamp and catheter products.
Observed potential for nsPFA to advance the standard of care for atrial fibrillation treatment.
Preliminary findings in first-in-human feasibility study using nsPFA surgical end-effector to ablate benign thyroid nodules validated engineering and potential for safe and effective human tissue ablation in surgery.
Focused on gaining clearance for a cardiac ablation clamp and advancing the catheter toward first-in-human studies.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...